## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLI	SHED U	NDER THE PATENT COOPERATION TREATY (PCT)
1) International Patent Classification 7:	$T^{-}$	(11) International Publication Number: WO 00/152
A61K 49/00	A2	(43) International Publication Date: 23 March 2000 (23.03.
1) International Application Number: PCT// 2) International Filing Date: 15 September 1999 40) Priority Data: 98117598.7 16 September 1998 (16.0) 71) Applicant (for all designated States except US): BIOGLAN PHARMA GMBH [DE/DE]; Am 11, D-86441 Zusmarshausen (DE). 72) Inventors; and 75 Inventors/Applicants (for US only): FRANK, Art Am Wasserberg 11, D-86441 Zusmarshause ANEITINO, Andreina [IT/IT]; Via Francesco I-00143 Roma (IT). 74) Agent: WIBBELMANN, Jobst; Wuesthoff & Schweigerstrasse 2, D-81541 München (DE).	9.98) GOLDHA Wasserb aur [DE/D n (DE). o Sapori,	BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, PMG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG).  Published  Without international search report and to be republication of that report.
(54) Title: RADIO-CONTRAST AGENTS (57) Abstract		and complete and c
(57) Abstract	oisomer o	f a compound with at least one chiral centre, wherein said stereoison administration, or is less chemotoxic, than at least one other stereois
(57) Abstract  An imaging or contrast agent comprising a stere in stereoisomeric excess and causes fewer adverse side	oisomer o	So companyed with at least one chiral centre, wherein said stereoison
(57) Abstract  An imaging or contrast agent comprising a stere in stereoisomeric excess and causes fewer adverse side	oisomer o	So companyed with at least one chiral centre, wherein said stereoison
(57) Abstract  An imaging or contrast agent comprising a stere in stereoisomeric excess and causes fewer adverse side	oisomer o	So companyed with at least one chiral centre, wherein said stereoison
(57) Abstract  An imaging or contrast agent comprising a stere in stereoisomeric excess and causes fewer adverse side	oisomer o	So companyed with at least one chiral centre, wherein said stereoison
(57) Abstract  An imaging or contrast agent comprising a stere in stereoisomeric excess and causes fewer adverse side	oisomer (	So companyed with at least one chiral centre, wherein said stereoison
(57) Abstract  An imaging or contrast agent comprising a stere in stereoisomeric excess and causes fewer adverse side	oisomer o	So companyed with at least one chiral centre, wherein said stereoison
(57) Abstract  An imaging or contrast agent comprising a stere in stereoisomeric excess and causes fewer adverse side	oisomer effects o	So companyed with at least one chiral centre, wherein said stereoison